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Abstract
Background. SPECT with radioligand DaTSCAN (SPECT-DaTSCAN) is a sensitive tool used for assessing the functional integrity of 
the presynaptic part of the nigrostriatal dopaminergic system. The procedure is useful whenever there is a need to distinguish 
between neurodegenerative parkinsonism and other parkinsonian syndromes in subjects with equivocal signs and symptoms. 
It can be assumed that the neurologist’s decision to perform SPECT-DaTSCAN depends on his or her experience and skill in the 
diagnosis of parkinsonian and tremor syndromes.
Aims. To assess the accuracy of referrals to SPECT-DATSCAN made by non-movement disorders specialists.
Material and methods. Sixty seven patients referred for SPECT-DaTSCAN by a general neurologist were studied. In all subjects, 
a movement disorder specialist performed the neurological examination, collected medical history, and analysed previous 
treatments and the results of diagnostic tests.
Results. Evaluation carried out by a movement disorder specialist did not confirm an indication for SPECT-DaTSCAN in 31 
patients (46.3%). General neurologists needed support for clinical diagnosis with SPECT-DaTSCAN most frequently in subjects 
with parkinsonism even though they were presenting a full-blown disease manifestation and even though the patients met the 
diagnostic criteria for Parkinson’s disease or one of the atypical parkinsonian syndromes.
Conclusions. Our presented results probably reflect the limited experience of general neurologists in the evaluation of 
parkinsonian syndromes and tremor. The use of SPECT-DaTSCAN by non-movement disorders specialists is associated with 
a significant risk of overuse of this tool. To minimise this risk, the skills of general neurologists in  diagnosing parkinsonian and 
tremor syndromes should be improved. Moreover, patients should be provided with access to movement disorders specialists.
Key words: SPECT-DaTSCAN, referrals, non-movement disorders specialists, movement disorders specialists 
(Neurol Neurochir Pol 2019; 53 (2): 138–143)
Introduction 
123[I]ioflupane ([123I]-fluoropropyl CIT, 123I-FP-CIT, 
DaTSCAN®, GE Healthcare) is a dopamine transporter (DAT) 
radioligand for single-photon emission tomography (SPECT). 
Degeneration of dopaminergic neurons in the substantia nigra 
results in reduced DAT concentration within the striatum, 
and therefore SPECT-DaTSCAN is used as a marker of the 
integrity of the presynaptic part of the nigrostriatal dopami-
nergic system [1–7]. 
DaTSCAN was approved by EMA in Europe in 2000 and 
by FDA in the USA in 2011 for the differential diagnosis of 
parkinsonian tremor and essential tremor (ET) and of Al-
zheimer’s disease (AD) and diffuse Lewy body disease (LBD) 
[8–10]. In clinical practice, SPECT-DaTSCAN has wider 
applications in that it allows for differential diagnosis between 
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neurodegenerative parkinsonisms on the one hand, and par-
kinsonian syndromes without the presynaptic involvement 
of the nigrostriatal dopaminergic system on the other hand.
It can be assumed that the neurologist’s decision to per-
form SPECT-DaTSCAN depends both on his or her expe-
rience and skill in the diagnosis of parkinsonian syndromes 
as well as on his or her knowledge of the usefulness and 
limitations of this technique. The aim of our paper was to 
assess the accuracy of referrals to SPECT-DATSCAN made 
by non-movement disorders specialists.
Material and methods 
At the Department of Nuclear Medicine, we introduced 
a routine procedure according to which the indications for all 
patients referred for SPECT-DaTSCAN were verified by one of 
two neurologists (AG or AB) with more than 15 years of expe-
rience in Parkinson’s disease and other movement disorders 
(> 50 patients seen per month). In all subjects, a neurological 
examination was performed, a medical history was carefully 
collected, and previous treatments and the available results of 
diagnostic tests were analysed.
Consecutive patients referred by a general neurologist 
from July 2016 to December 2017 were included in this 
present analysis.
The results presented in this paper are a retrospective 
analysis of data from routine practice and so there was no 
need to apply for the approval of the Bioethical Committee.
Results
Sixty seven patients referred for SPECT-DaTSCAN by 
a general neurologist were studied. Evaluation carried out by 
a movement disorder specialist did not confirm the indications 
for dopaminergic functional imaging in 31 patients (Group A), 
but found it to be reasonable in the other 36 subjects (Group B).
Group A. Patients with unconfirmed  
indications for SPECT-DaTSCAN study
In this group of 31 patients (Tab. 1), the largest subgroup 
consisted of 22 patients (age 52–91 years, disease duration 
1–16 years) who were referred for SPECT-DaTSCAN with an 
indication formulated by a general neurologist as „suspicion 
of PD”. In the opinion of a movement disorder specialist, the 
observed clinical symptoms were fully sufficient to diagnose 
PD in 12 subjects (aged 52–84, disease duration 1–5 years). All 
of them met the UK Brain Bank main diagnostic criteria for PD 
[12]: bradykinesia plus one or more of rigidity, tremor, or pos-
tural instability. Moreover, nine of these 12 (age 52–84 years, 
symptoms duration 2–5 years) presented with between  one 
and four of the supportive prospective positive criteria [12]: 
unilateral onset, rest tremor, progressive disorder, persistent 
asymmetry affecting the side of greatest onset, excellent (70–
100%) response to levodopa, and 1–4 years duration of illness. Ta
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ET [13] was diagnosed in three patients (two female and 
one male, 58–70 years) with 3–6 years history of symmetrical 
bilateral upper limb action and postural tremor. All these 
patients had also developed head tremor, but no signs of par-
kinsonism were observed. In two male subjects without par-
kinsonian signs, a diagnosis of essential tremor plus [13] was 
made. The first of these, a 78 year-old patient with a 16 years 
history of tremor, presented also with impaired tandem gait. 
The second of them, a 91 year-old subject, had suffered from 
kinetic and postural upper limb symmetric tremor and head 
“no-no” tremor for six years. Impairment of tandem gait was 
found, and his mother had also suffered from tremor.
In Group A there were also four patients with unquestio-
nable parkinsonian syndrome and other accompanying signs 
that allowed us to recognise one of the atypical parkinsonisms.
Two of these subjects met the diagnostic criteria for prob-
able multiple system atrophy (MSA) [14, 15]. A 54 year-old 
female had a three-year history of progressive, more or less 
symmetrical, bradykinesia and rigidity which did not respond 
to levodopa. She presented also with dysarthria, dysphagia, 
laryngeal stridor, cortical myoclonus of the fingers (poly-
minimyoclonus), ataxic gait, postural instability, Babinski sign 
and orthostatic hypotension manifesting with dizziness. In 
the second patient, a 63 year-old man, bradykinesia, rigidity 
(right ≥ left) and postural, rest and action tremor (right ≥ left) 
had progressed for four years, and these symptoms did not 
respond to levodopa. There was a history of REM behaviour 
disorder, dysphagia, urinary incontinence, and orthostatic 
hypotension. He presented moreover with cerebellar dysar-
thria, laryngeal stridor, tendency for a drooping head, ataxia 
and Babinski sign.
The next patient in this subgroup, a 67 year-old woman 
with a four-year disease duration presented with asymmetrical 
(right ≥ left) rigidity and bradykinesia with dystonic posture 
and alien limb syndrome on the right, apraxia dysgrapho-
esthesia of the right upper limb, and mild cognitive impair-
ment. She met the diagnostic criteria of probably corticobasal 
degeneration syndrome (CBS) [16].
A 68 year-old patient with a four-year history of fall-
ing backwards (observed from the first year of the disease), 
presented with — rather symmetrical — bradykinesia and 
rigidity, neck stiffness, tendency to retrocollis and verti-
cal gaze palsy. Brain MRI scans showed midbrain atrophy. 
Probable progressive supranuclear palsy (PSP) — PSP with 
Richardson’s syndrome — was diagnosed according to MDS 
diagnostic criteria [17]. 
Finally, there was a 78 year-old woman without any 
parkinsonian signs with diagnosis of depression made by 
a psychiatrist.
Among the patients with unconfirmed indications for the 
SPECT-DaTSCAN study there were seven subjects who were 
referred by a general neurologist due to tremor. 
In two female subjects (age 71 and 62 years, disease 
duration 15 and 4 years, respectively) dystonic tremor was 
diagnosed by the movement disorder specialist. In neither of 
them were there parkinsonian signs, while the examination re-
vealed the presence of mild torticollis and upper limbs dystonia. 
The next two females (78 and 68 years, disease duration 
7 and 6 years, respectively) presented with slightly asymmetric 
action tremor of upper limbs, impaired tandem gait and — in 
the first of them — memory impairment. No parkinsonian 
signs were present. Essential tremor plus [13] was diagnosed 
in both these cases.
Two female patients and one male patient (age 51, 55 and 
57 years, disease duration 3, 1 and 4 years, respectively) showed 
a full-blown asymmetric parkinsonian syndrome (including 
asymmetric rest tremor) which met the core UK Brain Bank 
criteria for Parkinson’s disease. In a male subject with a four-
year history of rest tremor, a good response to levodopa had 
been well documented.
A 39 year-old female (disease duration 1 year) was referred 
for SPECT-DaTSCAN as part of a differential diagnosis of 
psychogenic parkinsonism and PD. The patient reported 
many subjective complaints including pain and numbness 
located bilaterally within the feet, ankles and knees. Peripheral 
neuropathy and pathology within the spinal cord had been 
previously excluded. She did not meet the diagnostic criteria 
for restless legs syndrome. Her neurological examination was 
normal and, most of all, there were no parkinsonian signs. 
In the movement disorder specialist’s opinion, the patient’s 
symptoms were of psychogenic origin.
The last patient in Group A, a 61 year-old female, reported 
vertigo with onset one year ago. Her neurological examination 
was normal, and brain MRI scans suggested angioma within 
lenticular nucleus. According to the neurologist referring this 
subject for SPECT-DaTSCAN, the purpose of the study was 
„the assessment of dopaminergic system”.
In patients with unconfirmed indications for SPECT-
DaTSCAN, the study was not performed. The exception was 
two patients with a diagnosis of atypical parkinsonism made 
by the movement disorders specialist; in these cases, the 
SPECT-DaTSCAN result was abnormal.
Group B. Patients with confirmed indications 
for SPECT-DaTSCAN
In the opinion of movement disorder specialists, the 
decision to perform the SPECT-DaTSCAN study was well-
-founded in 17 female and 18 male subjects (Tab. 2).
In 16 patients (nine women and seven men, age range 
37–57 years; disease duration 1–4 years), the imaging study 
was a part of the process of differential diagnosis between 
essential tremor and PD. At this point, in all these cases, it 
was indeed difficult or impossible to make a diagnosis solely 
on the basis of clinical symptoms.
The next subgroup consisted of four male patients (age 
range 61–77, disease duration 2–6 years), who required dif-
ferential diagnosis between vascular and neurodegenerative 
parkinsonism, especially PD.
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Three men and one woman (aged 37–51 years, disease 
duration 1–2 years) suspected by the referring neurologist for 
Parkinson’s disease, presented with different combinations of 
two core UK Brain Bank criteria parkinsonian signs, but they 
did not meet the diagnosis of PD.
Furthermore, five patients (three females and two males, 
age 58–67, disease duration 3–7 years) were classified as 
Clinically Uncertain Parkinsonian Syndrome (CUPS). They 
did not meet the diagnostic criteria for PD or any atypical 
parkinsonism, and there was a poor response to levodopa, so 
drug-induced parkinsonism was excluded.
Two patients (a 41 year-old female and a 37 year-old male, 
both with three years of symptoms duration) with uncertain 
symptoms suggesting MSA and a man (62 years, disease du-
ration 2 years) presenting with scant symptoms and suspected 
of PSP were also qualified for SPECT-DaTSCAN to support 
the pre-scan diagnosis.
The need to perform the SPECT study was confirmed also 
in a 69 year-old woman (symptoms duration 2 years) with 
axonal polyneuropathy and asymmetric (L > P) postural, rest 
and action tremor. The aim was to confirm or to exclude the 
co-occurrence of neurodegenerative parkinsonism.
In another 39 year-old female patient, writer’s cramp had 
developed when she was about 20 and subsequently dystonia 
spread to the contralateral upper limb. Neurological exami-
nation revealed unilateral bradykinesia and rigidity. Neither 
dystonia nor parkinsonian signs responded to levodopa. Diffe-
rential diagnostics between dystonia-parkinsonism syndrome 
and neurodegenerative parkinsonism required imaging of the 
nigrostriatal dopaminergic system.
Finally, we accepted a 59 year-old woman who had 
been treated with neuroleptics for many years before acute, 
asymmetric parkinsonism had developed. The purpose of the 
SPECT study in this case was to exclude the co-existence of 
nigrostriatal degeneration.
Discussion
The concentration and distribution of DAT within the 
striatum reflect the number of active dopaminergic neurons 
in the substantia nigra. SPECT-DaTSCAN is a sensitive tool 
for assessing the functional integrity of the presynaptic part 
of the nigrostriatal dopaminergic system [1–7]. DaTSCAN 
is currently approved in Europe and the USA for use in the 
differential diagnosis between PD tremor and essential tremor 
as well as for differentiation between AD and LBD. However, 
in clinical practice, SPECT-DaTSCAN is used much more 
widely and may be useful whenever there is a need to distin-
guish between neurodegenerative parkinsonism (PD, MSA, 
PSP, CBS) and parkinsonian syndromes not resulting from 
damage to the dopaminergic system in subjects with equivocal 
signs and symptoms (DIP, PP, VP) [18].
SPECT-DaTSCAN is a very sensitive functional marker of 
the lesion of the presynaptic part of the nigrostriatal system 
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and – according to new MDS diagnostic criteria [19] – nor-
mal dopaminergic imaging is an absolute exclusion criterion 
for PD. SPECT-DaTSCAN is not recommended as a part of 
routine diagnostic procedure because in patients who meet 
the UK Brain Bank diagnostic criteria for PD the results of 
dopaminergic imaging are abnormal [12]. The same applies 
to atypical parkinsonisms if the main signs of parkinsonian 
syndrome are present [14–17]. Moreover, SPECT-DaTSCAN 
is completely useless in the differential diagnosis of neurode-
generative parkinsonisms: PD, MSA, PSP and CBS [20–23]. 
The usefulness of SPECT-DaTSCAN in the practice of 
movement disorders centres has been confirmed by numerous 
reports.  At referral movement disorders centres, the diagnosis 
and treatment were changed in more than half of the patients 
as a result of dopaminergic imaging [24–25]. 
SPECT-DaTSCAN is a relatively expensive procedure, and 
therefore the rational use of this diagnostic tool is of particular 
importance. The British NICE 2017 [11] guidelines underline 
that this procedure may eliminate the costs of unnecessary 
treatment of patients with a false positive diagnosis based on 
a neurological examination. On the other hand, it has been 
suggested that SPECT-DaTSCAN should not be used in all 
subjects suspected of PD, and it is recommended that this 
procedure “should be available to specialists with expertise 
in its use and interpretation”. 
Until 2018, the availability of SPECT-DaTSCAN in Poland 
was very limited. However, at the Department of Nuclear 
Medicine in Medical University of Łodź a number of patients 
could be tested without any payment from their side (the 
procedure was funded by the Regional Branch of the National 
Health Fund). Patients could be referred by both movement 
disorder specialists and neurologists with no special interest in 
movement disorder (i.e. non-movement disorders specialists, 
general neurologists).
There are no reference centres for neurological subspe-
cialties within the Polish healthcare system. Patients with 
Parkinson’s disease and other movement disorders are diag-
nosed and treated by general neurologists who have differing 
levels of experience in this area and who are usually not able 
to refer patients to a movement disorders specialist for con-
sultation. There is therefore a risk that the SPECT-DaTSCAN 
will be overused in this situation. 
To the best of our knowledge, this is the first study to 
have assessed the correctness of non-movement disorders 
specialists’ decision to use SPECT-DaTSCAN in routine 
clinical practice. 
We evaluated 67 patients referred by general neurologists 
for dopaminergic imaging to the Department of Nuclear 
Medicine. In 31 (46.3%) of these subjects, in the opinion 
of movement disorders specialists, it was possible to make 
a diagnosis without a SPECT study, solely on the basis of 
neurological examination and data from medical history. 
Non-movement disorders specialists needed support for cli-
nical diagnosis with SPECT-DaTSCAN most often in cases of 
parkinsonism. It should be noted that this concerned patients 
who had been ill for several years and had full-blown disease 
symptoms. The same problem occurred in subjects with 
tremor. This, in our opinion, most likely reflects the limited 
experience of this group of neurologists in the diagnosis of 
tremor and parkinsonian syndromes.
The general neurologists who referred patients to the 
Department of Nuclear Medicine were not obliged to provide 
alternative diagnoses which, according to them, needed diffe-
rentiation using SPECT-DaTSCAN. Therefore, we could not 
assess to what extent the choice of SPECT-DaTSCAN as a tool 
to resolve the neurologist’s uncertainty regarding the pre-scan 
diagnosis considered this technique’s basic application, i.e. 
the distinction between degenerative and non-degenerative 
parkinsonisms.
In the group of patients with confirmed indications for 
the SPECT-DaTSCAN study, there were several subjects 
in whom the signs and symptoms revealed by neurologi-
cal examination were insufficient to make a diagnosis. In 
these cases, the abnormal result of imaging could confirm 
the presence of nigrostriatal degeneration and enable early 
diagnosis. This was a finely balanced decision, because in 
these cases longer clinical observation would probably also 
allow for diagnosis.
The presented results show that the use of SPECT-
DaTSCAN by non-movement disorders specialists is associa-
ted with a significant risk of overuse of this diagnostic tool. To 
minimise this risk, general neurologists’ skills in diagnosing 
parkinsonian syndromes should be improved, and at the same 
time patients should be provided with access to a movement 
disorders specialist. In addition, broad access to DaTSCAN 
financed by the National Health Fund should be connected 
to an educational programme addressed to all neurologists.
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